Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENCORE1 neurocognitive substudy in HIV
ACTRN12612000622808Phase 3Active, not recruiting
- Sponsor
- The Kirby Institute
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Primary endpoint: Comparison of neurocognitive function between efavirenz dose groups. Started Jan 2012; status: active, not recruiting.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12612000622808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000622808.